Monoclonal antibody-drug conjugateFDA-approvedSecond-line
Brentuximab vedotin
How it works
Binds to CD30 on the surface of cancer cells, delivering a toxic payload that kills the cells.
Cancer types
Leukemia— CD30-positive
Efficacy
In clinical trials, around 75% of patients with relapsed or refractory Hodgkin lymphoma achieved a complete or partial response, with a median progression-free survival of approximately 1 year.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Brentuximab Vedotin for Malignant Mesothelioma | Lung Cancer | phase-2 | — | Source → |
| New Treatment Approach for Rare Cancer in Older Patients | Leukemia | phase-2 | — | Source → |
| Combination Therapy Shows Promise in Treating Advanced Lung and Skin Cancer | Melanoma | phase-2 | For the secondary refractory metastatic non-small cell lung cancer cohort, the ORR was 14%, median PFS was 5.85 months, and median OS was 14.4 months. For the secondary refractory metastatic cutaneous melanoma cohort, the ORR was 24%, median PFS was 4.44 months, and median OS was 21.9 months. | Source → |
| Brentuximab Vedotin Shows Promise in Treating Breast Cancer and Lymphoma | Breast Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.